ArticleInternational journal of nanomedicine2025
Fabrication of Nano-Silver Composite Using
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Study aims to optimize the synthesis conditions for silver nanoparticle composites [ALP(D)-AgNPs] using a rapid and environmentally friendly method and investigate the antioxidant, antibacterial, and anticancer activities of the fabricated composite. Methods: The polysaccharide component ALP-D was extracted and purified from the fruits of Results: Single-factor experiments identified the optimal synthesis conditions for ALP(D)-AgNPs as a reaction time of 180 min, a temperature of 100 °C, and a 10:1 volume ratio of silver nitrate to ALP-D. The free radical scavenging activity of ALP(D)-AgNPs against DPPH and ABTS was significantly enhanced compared with that of ALP-D. The minimum inhibitory concentration (MIC) values of ALP(D)-AgNPs against E coli and B subtilis were 31.25 μg/mL, while the MIC value against S aureus was 62.5 μg/mL. The minimum bactericidal concentration (MBC) values of ALP(D)-AgNPs were 125 μg/mL for E coli, B subtilis, and S aureus. The IC50 values of ALP(D)-AgNPs on the MDA-MB-231, HepG2, Caco-2, and C6 cancer cell lines were 14.72 ± 0.23, 8.19 ± 0.65, 22.73 ± 3.01, and 15.77 ± 2.91 μg/mL, respectively. Conclusion: In summary, we have identified a novel material for the green synthesis of silver nanoparticles. The results show the ALP(D)-AgNPs synthesized using the new material ALP-D exhibit excellent stability and dispersibility. Furthermore, the biological activity reveals that ALP(D)-AgNPs possess notable antioxidant, antibacterial, and cancer-suppressing activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.